Search Results for: TG Therapeutics Announces Completion of
Articles
September 11, 2017
TG Therapeutics Announces Completion of Target Enrollment in Phase 3 Trial September 11, 2017
TG Therapeutics, Inc. recently announced that target enrollment for the UNITY-CLL Phase 3 trial has been achieved. The UNITY-CLL Phase...
February 26, 2024
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600 February 26, 2024
Biora Therapeutics, Inc. recently announced completion of the single-ascending dose (SAD) cohorts for its Phase 1, first-in-human clinical study of...
December 11, 2023
Biora Therapeutics Announces New Research Collaboration for the BioJet Systemic Oral Delivery Platform December 11, 2023
Biora Therapeutics, Inc. recently announced a new research collaboration with a large pharmaceutical company for its BioJet Systemic Oral Delivery Platform. The new agreement provides funding….
November 9, 2023
Recursion Announces Data Collaboration Deal With Tempus & Updated Focus of Collaboration With Bayer November 9, 2023
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio….
September 6, 2023
Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial in Metastatic Pancreatic Ductal Adenocarcinoma September 6, 2023
Lisata Therapeutics, Inc. recently announced a positive outcome of the prespecified interim futility analysis for the ASCEND trial, a Phase...
August 30, 2023
Denali Therapeutics Announces New Interim Data From Phase 1/2 Study of DNL310 in MPS II (Hunter Syndrome) August 30, 2023
Denali Therapeutics Inc. recently announced new interim data from the ongoing open-label, single-arm Phase 1/2 study of DNL310 (ETV:IDS) in...
June 27, 2023
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma June 27, 2023
Harpoon Therapeutics, Inc. recently announced the completion of planned patient enrollment in the Phase 1 dose escalation study evaluating the...
June 6, 2023
Anavex Life Sciences Announces Completion of Phase 2/3 Rett Syndrome Clinical Trial June 6, 2023
Anavex Life Sciences Corp. recently announced the completion of dosing of all participants of the placebo-controlled EXCELLENCE Phase 2/3 study...
May 23, 2023
AnaMar Announces Positive Phase 1 Data for its Phase 2 Ready Compound for Treating Fibrosis May 23, 2023
AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, recently announced...
March 23, 2022
4D pharma Announces Positive Interim Results From Phase 1/2 Study March 23, 2022
4D pharma plc recently announced that in Part B of its signal finding study of MRx0518 in combination with MSD’s...
January 19, 2022
VYNE Therapeutics Announces Phase 1b Data for FMX114 From Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis January 19, 2022
VYNE Therapeutics Inc. recently announced it has completed the Phase 1b portion of a Phase 1b/2a clinical trial evaluating FMX114...
July 1, 2021
Altimmune Announces Update on AdCOVID Phase 1 Clinical Trial July 1, 2021
Altimmune, Inc. recently provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The company also provided...
May 26, 2021
Onconova Therapeutics Announces Initial Dosing of First Patient in US Phase 1 Clinical Trial May 26, 2021
Onconova Therapeutics, Inc. recently announced the first patient has been dosed in the US Phase 1 clinical trial of ON...
September 18, 2019
Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 Trial September 18, 2019
Ovid Therapeutics Inc. recently announced the first patient has been randomized in the company’s single, pivotal Phase 3 NEPTUNE clinical...
June 6, 2018
MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM June 6, 2018
MimiVax LLC recently announced positive interim results from a multicenter Phase II study of SurVaxM in patients with newly diagnosed glioblastoma (nGBM).
February 7, 2017
Gemphire Announces Interim LDL-C Lowering Data From Clinical Trial February 7, 2017
Gemphire Therapeutics Inc. recently announced interim data on the LDL-C primary endpoint from the ongoing open label COBALT-1 trial. COBALT-1 is...
January 26, 2024
DRUG DEVELOPMENT - Using a Novel Deep Cyclic Inhibition Mechanism to Treat Broad Range of RAS-Mutant Cancers January 26, 2024
Ben Zeskind, PhD, addresses the question: rather than targeting individual RAS mutations and treating chronically, is it possible to achieve broad therapeutic activity in a way that focuses on malignant cells while minimizing damage to healthy cells?
June 25, 2012
6/27/2012 June 25, 2012
Hovione Reports Significant Sales Growth Hovione recently announced that the consolidated sales for the fiscal year ended March 2012 amounted...
June 11, 2012
6/13/2012 June 11, 2012
Particle Sciences Expands cGMP Capabilities With Addition of Thin Films Particle Sciences recently announced it has added new coating capabilities...
